Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $755.00 at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target trimmed by Morgan Stanley from $958.00 to $755.00 in a report released on Monday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

REGN has been the topic of several other research reports. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective on the stock. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. Finally, Bank of America reduced their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $847.40.

Regeneron Pharmaceuticals Stock Up 0.1%

NASDAQ REGN opened at $490.81 on Monday. The firm has a market cap of $52.99 billion, a PE ratio of 12.82, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals has a one year low of $481.58 and a one year high of $1,211.20. The stock’s 50 day simple moving average is $581.26 and its 200 day simple moving average is $663.80. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the company earned $9.55 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. Activest Wealth Management grew its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Finally, Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.